Soterios Pharma

Executive Summary

Soterios Pharma is a UK-based biotechnology company dedicated to developing innovative therapies for dermatological diseases with high unmet medical need, with an initial focus on alopecia areata, particularly the mild-to-moderate patient segment. The company leverages deep scientific expertise in medical dermatology to identify de-risked drug candidates, aiming to provide effective and safe treatments. While still in early stages, Soterios Pharma's targeted approach addresses a significant patient population lacking approved therapies, positioning it for potential growth. The company is privately held and has not disclosed funding or valuation details, but its focus on a niche dermatological indication may attract strategic partnerships or investment as clinical programs advance.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for lead alopecia areata candidate45% success
• H2 2026Potential partnership or licensing deal for dermatology portfolio50% success
• Q4 2026Series A or seed funding announcement60% success